CETP基因TaqI B多态性与瑞苏伐他汀对糖耐量异常合并冠心病患者疗效的相关性  

Association of TaqI B polymorphisms of CETP gene and Rosuvastatin with the curative effect of CHD patients with IGT

作　　者：杨希立[1] 许兆延[1] 张健瑜[1] 周昭仑[1] 李健民[1] 蔡炜标[1] 李健[1] 岑锦明[1] 

机构地区：[1]广东省佛山市第一人民医院心血管内科,528000

出　　处：《实用医学杂志》2016年第20期3416-3418,共3页The Journal of Practical Medicine

基　　金：广东省科技计划项目(编号:2011B031800193)

摘　　要：目的:比较血糖异常合并冠心病组瑞舒伐他汀治疗前后的血脂指标和冠状动脉粥样硬化斑块变化间的关系。方法:血糖异常合并冠心病患者196例及血糖正常160例给予瑞苏伐他汀治疗,分析病例组治疗前后冠脉斑块的血管内超声(intravascular ultrasound,IVUS)结果以及血脂变化情况,用飞行时间质谱检测研究对象血标本的CETP基因TaqI B单核苷酸多态性(SNPs)位点。结果:CETP基因TaqI B B1B1、B1B2、B2B基因型在病例组的分布频率分别为35.7%、48.0%,16.3%;对照组为31.3%、53.1%、15.6%。HDL-C及MLA在瑞苏伐他汀治疗后呈上升趋势,LDL-C、TG、TCH、Lpa、PA、EEMA及PB治疗后呈下降趋势。结论:CETP基因Taql B多态性与瑞苏伐他汀对冠心病患者的血脂调节以及血管斑块退缩作用可能有相关性。Objective To compare the changes of plasma lipid indexes and coronary artery atherosclerotic plaque in TaqI B genotypes in CHD patients with impaired glucose tolerance（IGT） before and after statin therapy. Methods A total of 196 CHD with IGT and 160 controls were included. The changes of plasma lipid indexes and coronary artery atherosclerotic plaque in TaqI B genotypes were analyzed before and after Rosovastatin therapy. Sequenom Mass ARRAY platform was used to detect the CETP TaqI B SNPs. Results The genotype frequency of the B1B1, B1B2 and B2B2 in CHD with IGT group was 35.7%, 48.0% and 16.3% respectively,while in control group was 31.3%, 53.1% and 15.6% respectively. HDL-C, PA and MLA levels increased after Rosuvastatin therapy, while LDL-C, TG, TCH, Lpa, PA, EEMA and PB levels decreased. Conclusions CETP gene polymorphisms TaqI B would have association with the effects of Rosuvastatin therapy in the CHD with IGT.

关 键 词：冠心病 胆固醇酯转运蛋白 瑞苏伐他汀 基因多态性 血管内超声 血糖异常 

分 类 号：R541.4[医药卫生—心血管疾病]